Investing.com - Piper Sandler raised its price target on CRISPR Therapeutics stock (NASDAQ:CRSP) to $110 from $105 while maintaining an Overweight rating following the company’s convertible note offering. The stock currently trades at $48.42 with a market cap of $4.68 billion, down 8.3% over the past week.
CRISPR Therapeutics issued $600 million in convertible notes due in March 2031, convertible at $76.56 per share with an effective coupon of 1.73%. Piper Sandler estimates the company now holds pro forma cash of $2.56 billion. According to InvestingPro, the company holds more cash than debt on its balance sheet, with an overall financial health score rated as "Fair." For deeper insights, investors can access the comprehensive Pro Research Report, available for CRSP and 1,400+ other US stocks.
Partner Vertex Pharmaceuticals (NASDAQ:VRTX) plans to submit global regulatory filings for CASGEVY for children with sickle cell disease and transfusion-dependent beta-thalassemia in the first half of 2026. Vertex will use a priority review voucher for expedited FDA review.
Piper Sandler forecasts CASGEVY revenues of $300 million on 150 patients to turn the joint venture profitable in 2026. CRISPR Therapeutics will report Phase I data on zugo-cel in autoimmune disease and B-Cell lymphoma in the second half of 2026.
The company will initiate Phase I studies of CTX340 in the first half of 2026 and CTX460 in mid-2026. CRISPR Therapeutics will report Phase Ib data on CTX310 and proof-of-concept Phase II data on CTX611 in total knee arthroplasty patients in the second half of 2026.
In other recent news, CRISPR Therapeutics AG announced the pricing of $550 million in convertible senior notes due 2031, marking an increase from the initially planned $350 million. The company has also granted initial purchasers an option to buy an additional $50 million in notes, with the sale expected to close in March 2026. Meanwhile, Citizens analyst adjusted the price target for CRISPR Therapeutics to $80, down from $86, while maintaining a Market Outperform rating. This adjustment reflects a shift in valuation focus toward the company’s in-vivo assets. Additionally, CRISPR Therapeutics reported promising preliminary results for its investigational CD19-targeting allogeneic CAR T therapy, zugocaptagene geleucel (zugo-cel), in treating autoimmune diseases and blood cancers. Patients treated with zugo-cel demonstrated significant clinical improvement, with one systemic lupus erythematosus patient achieving remission for six months. These developments highlight CRISPR Therapeutics’ ongoing efforts in advancing its therapeutic pipeline and financial strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for VRTX plus thousands of other stocks and find your next hidden gem with massive upside.